Abstract:
BACKGROUND:In this analysis we compared quality-adjusted survival outcomes between nab-paclitaxel (nab-P) and standard paclitaxel (Pac) using data from the nab-P phase III registration trial in metastatic breast cancer. PATIENTS AND METHODS:Quality-adjusted overall survival was estimated using the quality-adjusted time without symptoms or toxicity (Q-TWiST) approach. Overall survival was partitioned into time without progression/Grade ≥ 3 adverse events (AEs) toxicity (TWiST), time with Grade ≥ 3 AE toxicity (TOX), and time after relapse (REL). Q-TWiST was calculated by multiplying mean time in each health state by its assigned utility (base-case utility values: time without symptoms of disease progression or toxicity of Grade ≥ 3 adverse events [TWiST] = 1.0, TOX = 0.5, and REL = 0.5). In threshold analyses, TOX and REL varied from 0.0 to 1.0 whereas TWiST was maintained at 1.0. Comparisons were made for the intent-to-treat population and the subset of patients initiating the study drugs as second or subsequent lines (2L+) of chemotherapy (per approved nab-P indication; 2L+ subpopulation). A ≥ 15% relative Q-TWiST gain (vs. mean Pac overall survival) was considered clearly clinically important. RESULTS:In the intent-to-treat population, nab-P (n = 229) versus Pac (n = 225) resulted in nonsignificant gains of 1.4 months of mean Q-TWiST (11.6 vs. 10.2 months; 95% confidence interval [CI], -0.03 to 2.8). In the 2L+ subpopulation, nab-P (n = 132) versus Pac (n = 136) resulted in a statistically significant gain of 2.2 months of mean Q-TWiST (10.5 vs. 8.4 months; 95% CI, 0.6-3.8), with a 17.1% relative Q-TWiST gain (threshold analysis range, 14.0%-19.5%, both figures significant). CONCLUSION:In its approved indication for metastatic breast cancer, nab-P showed a statistically significant and clearly clinically important improvement in quality-adjusted survival time versus Pac in the 2L+ subpopulation.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
Cortes J,Pérez-García J,Whiting S,Wan Y,Solem C,Tai MH,Margunato-Debay S,Ko A,Fandi A,Botteman Mdoi
10.1016/j.clbc.2018.03.014subject
Has Abstractpub_date
2018-10-01 00:00:00pages
e919-e926issue
5eissn
1526-8209issn
1938-0666pii
S1526-8209(17)30778-4journal_volume
18pub_type
杂志文章abstract:BACKGROUND:Seromas constitute a common complication following surgery for breast cancer, and closed drainage is used routinely to reduce its incidence. The aim of this study was to evaluate the influence of number of drains on patient discomfort, seroma formation, and hospital stay during the immediate postoperative pe...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2009.n.041
更新日期:2009-11-01 00:00:00
abstract:BACKGROUND:Nanoparticle albumin-bound paclitaxel (nab-P) and bevacizumab have each demonstrated efficacy in patients with MBC. This trial was designed to further develop nab-P by evaluating its efficacy and safety using every 3 weeks (q3w), every 2 weeks (q2w), or weekly scheduling in combination with bevacizumab as fi...
journal_title:Clinical breast cancer
pub_type: 杂志文章,随机对照试验
doi:10.1016/j.clbc.2013.02.008
更新日期:2013-08-01 00:00:00
abstract:BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.05.007
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS:Eight hundred women were i...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.07.007
更新日期:2016-12-01 00:00:00
abstract:BACKGROUND:Following treatment for breast cancer, many young women are interested in having a child. There are few data available regarding actual fertility and menopausal outcomes in young breast cancer survivors. We evaluated these outcomes among young breast cancer survivors in collaboration with the Young Survival ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2008.n.004
更新日期:2008-02-01 00:00:00
abstract:BACKGROUND:Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2(+)) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotox...
journal_title:Clinical breast cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/j.clbc.2015.10.005
更新日期:2016-02-01 00:00:00
abstract:BACKGROUND:The adoption of hypofractionated radiotherapy (HFRT) into clinical practice varies widely despite randomized trials and guidelines supporting its equivalence to conventional fractionated radiotherapy (CFRT) for certain patient populations. We assessed the use of HFRT at a single institution from 2011 to 2018...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.03.006
更新日期:2020-10-01 00:00:00
abstract::Kaposiform hemangioendothelioma (KHE) is a locally aggressive vascular tumor that usually occurs in infants. It is commonly associated with Kasabach-Merritt syndrome and lymphangiomatosis. It generally originates on the skin, later affecting deeper tissue by infiltrative growth. Although visceral involvement is very u...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2011.03.008
更新日期:2011-04-01 00:00:00
abstract:PURPOSE:Oncotype DX (ODX) predicts breast cancer recurrence risk, guiding the choice of adjuvant treatment. In many countries, access to the test is not always available. We used correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC), and recurrence score (RS) assessed...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.04.012
更新日期:2020-10-01 00:00:00
abstract::According to the World Health Organization (WHO) published data in 2015; breast cancer is the most prevalent and the second leading cause of cancer death among females. As approximately 70% of breast cancer tumor cells are estrogen receptor (ER) positive, primary therapeutic agents such as Anti-estrogens were produced...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.1016/j.clbc.2017.03.013
更新日期:2017-10-01 00:00:00
abstract::In addition to classical clinicopathologic factors, such as hormone receptor positivity, human epidermal growth factor receptor 2 (HER2) status, and tumor size, grade, and lymph node status, a number of commercially available genomic tests may be used to help inform treatment decisions for early breast cancer patients...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.1016/j.clbc.2020.01.001
更新日期:2020-06-01 00:00:00
abstract::Breast cancer stem cells (BCSCs), characterized by the CD44(+)/CD24(-/low) marker, are attributed with features that are demonstrated by the disease itself, such as growth of tumor, recurrence, metastases, and multiple drug resistance. This review concerns the emergence and expediency of BCSCs in treating relapse and ...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.1016/j.clbc.2012.09.017
更新日期:2013-02-01 00:00:00
abstract::Women with germline mutations in BRCA1 or BRCA2 are known to be at substantially elevated risk for breast cancer. With increasing acceptance of genetic testing, significant numbers of mutation carriers are being identified, but evidence-based guidelines for the management of women at hereditary risk are lacking. This ...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2004.n.029
更新日期:2004-10-01 00:00:00
abstract:INTRODUCTION:Implant-sparing mastectomy (ISM) is a skin-sparing mastectomy that preserves a retropectoral implant and potentially eliminates the need for tissue expansion or complex reconstruction. This study aimed to determine oncologic and surgical outcomes and reconstructive patterns in patients undergoing ISM. PAT...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2019.08.007
更新日期:2020-02-01 00:00:00
abstract:BACKGROUND:We studied the extent of BRCA1/2 genetic testing to help select the surgical approach for patients with breast cancer in Japan remains unclear. PATIENTS AND METHODS:The study subjects were female patients with primary unilateral invasive breast cancer considered as candidates for breast-conserving surgery w...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.08.004
更新日期:2020-08-20 00:00:00
abstract:INTRODUCTION:For patients who have an ipsilateral breast cancer recurrence following prior breast-conserving surgery and radiation, total mastectomy generally is recommended. However, little is known about the suitability and outcomes of nipple-sparing mastectomy (NSM) with immediate breast reconstruction for the treat...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.10.011
更新日期:2017-07-01 00:00:00
abstract:BACKGROUND:Irinotecan has a 20% to 25% response rate (RR) in patients with previously treated metastatic breast cancer (MBC). Epidermal growth factor receptor (EGFR) is overexpressed in some MBC, especially in triple-negative breast cancer (TNBC). Cetuximab is a monoclonal antibody against EGFR with additive preclinica...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2015.08.002
更新日期:2016-02-01 00:00:00
abstract::Fulvestrant, an estrogen receptor antagonist that downregulates the estrogen receptor but has no known agonist effects, has been evaluated in 2 randomized trials involving postmenopausal women with hormone receptor-positive, progressive advanced-stage breast cancer after disease progression with antiestrogen therapy. ...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2005.s.009
更新日期:2005-04-01 00:00:00
abstract:INTRODUCTION:The purpose of this study was to evaluate the added value of breast magnetic resonance imaging (MRI) in preoperative diagnosis of ductal carcinoma in situ (DCIS). We reviewed our institution database of 3499 consecutive patients treated for breast cancer. PATIENTS AND METHODS:A total of 362 patients with ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.12.007
更新日期:2017-06-01 00:00:00
abstract:BACKGROUND:Arm lymphedema is a common complication after axillary lymph node dissection (ALND), and there is no effective treatment. The clinical significance of sentinel lymph node biopsy (SLNB) is to avoid the risk of arm lymphedema caused by ALND in cases in which the nodes are negative for cancer cells. In develope...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2012.10.005
更新日期:2013-06-01 00:00:00
abstract:BACKGROUND:Volume displacement techniques that use remnant breast tissue are useful in reconstructive procedures after partial mastectomy. The authors analyzed the oncologic results of volume displacement surgery after partial mastectomy and their associations with various clinicopathologic factors. PATIENTS AND METHO...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.06.018
更新日期:2017-02-01 00:00:00
abstract:BACKGROUND:The study aimed to evaluate the feasibility and reliability of ultrasound-guided vacuum-assisted breast biopsy (US-VABB) for sampling of microcalcifications indicative of cancer when stereotactic vacuum-assisted breast biopsy cannot be performed because of reasons such as thin breast tissue, insufficient thi...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.12.002
更新日期:2019-04-01 00:00:00
abstract:BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2015.04.008
更新日期:2015-12-01 00:00:00
abstract:BACKGROUND:Although magnetic resonance imaging (MRI) is a useful imaging modality for invasive cancer, its role in preoperative surgical planning for ductal carcinoma in situ (DCIS) has not been established. We sought to determine whether preoperative MRI affects surgical treatment and outcomes in women with pure DCIS....
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2011.n.006
更新日期:2011-03-01 00:00:00
abstract:BACKGROUND:Radiation therapy (RT) is often delivered after lumpectomy for women with breast cancer. A common perceived side effect of RT is fatigue, yet its exact effect on activity levels and sleep is unknown. In this study we analyzed the change in activity levels and sleep using an activity tracking device before, d...
journal_title:Clinical breast cancer
pub_type: 临床试验,杂志文章
doi:10.1016/j.clbc.2017.08.009
更新日期:2018-02-01 00:00:00
abstract:UNLABELLED:Analysis of magnetic resonance imaging-guided breast biopsies yielding high-risk histopathologic features at a single institution found an overall upstage rate to malignancy of 14% at surgical excision. All upstaged lesions were associated with atypical ductal hyperplasia. Flat epithelial atypia and atypical...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2014.12.005
更新日期:2015-06-01 00:00:00
abstract:INTRODUCTION:Unwanted clinical variation is common across the United States health care system and is particularly vexing in oncology owing to the complexity, morbidity, and high cost of the disease. Efforts to standardize care including guidelines and continuing medical education have had only limited impact. Disease-...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.12.010
更新日期:2019-04-01 00:00:00
abstract:PURPOSE:To evaluate the use of radiotherapy (RT) in older patients with triple-negative breast cancer (TNBC). PATIENTS AND METHODS:The National Cancer Data Base (NCDB) is a comprehensive national database that captures approximately 70% of newly diagnosed cancer patients in the United States. Data for patients meeting...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.05.011
更新日期:2016-08-01 00:00:00
abstract:INTRODUCTION:There is only limited data from clinical practice on the relevance of body mass index (BMI) on pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). PATIENTS AND METHODS:The impact of BMI on pCR and survival outcome was examined in 324 patients wi...
journal_title:Clinical breast cancer
pub_type: 杂志文章,meta分析
doi:10.1016/j.clbc.2016.02.018
更新日期:2016-08-01 00:00:00
abstract::Breast cancer is one of the most commonly diagnosed types of cancer in women. Its pathogenesis involves genetic, hormonal, and environmental factors. A large body of evidence indicates that physical activity has positive effects on every aspect of breast cancer evolution, including prevention, medical treatment, and a...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.1016/j.clbc.2017.05.003
更新日期:2017-10-01 00:00:00